L. Moreau

1.5k total citations
36 papers, 640 citations indexed

About

L. Moreau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, L. Moreau has authored 36 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in L. Moreau's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (14 papers) and Neuroendocrine Tumor Research Advances (6 papers). L. Moreau is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (14 papers) and Neuroendocrine Tumor Research Advances (6 papers). L. Moreau collaborates with scholars based in France, United States and Japan. L. Moreau's co-authors include Élisabeth Quoix, Ashok Purohit, U. Gatzemeier, Jean-Louis Pujol, Gary Richardson, Claus Steppert, Alain Rivière, Malcolm Ranson, Joachim von Pawel and Stephan Bildat and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

L. Moreau

33 papers receiving 615 citations

Peers

Countries citing papers authored by L. Moreau

Since Specialization

Citations

This map shows the geographic impact of L. Moreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Moreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Moreau more than expected).

Fields of papers citing papers by L. Moreau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Moreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Moreau. The network helps show where L. Moreau may publish in the future.

Co-authorship network of co-authors of L. Moreau

This figure shows the co-authorship network connecting the top 25 collaborators of L. Moreau. A scholar is included among the top collaborators of L. Moreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Moreau. L. Moreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	486MO Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC) 2025 ·Annals of Oncology ·E. Mayer, (unknown), (unknown), W Janni, X. Cynthia, (unknown), Giampaolo Bianchini, Hiroaki Iwata, (unknown), Adam Brufsky, (unknown), Javier Pascual, L. Moreau, (unknown), Nuri Karadurmuş, Cara Arizmendi, Stephen B. Fox, (unknown), Cynthia Huang Bartlett, Nicholas C. Turner	1
2	OA05.02 First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial 2025 ·Journal of Thoracic Oncology ·Céline Mascaux, Laurent Greillier, L. Moreau, Thomas Egenod, (unknown), (unknown), (unknown), O. Molinier, Marie Wislez, (unknown), (unknown), Éric Pichon, (unknown), (unknown), (unknown), Perrine Masson, Alexandra Langlais, (unknown), Élisabeth Quoix, (unknown)	0
3	1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial 2024 ·Annals of Oncology ·(unknown), Laurent Greillier, Céline Mascaux, (unknown), D. Carmier, L. Moreau, Benoît Roch, D. Debieuvre, X. Dhalluin, (unknown), (unknown), Audrey Rabeau, (unknown), A. Dixmier, Charles Naltet, Antoine Khalil, (unknown), Alexandra Langlais, (unknown), M. Duruisseaux	0
4	Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study 2020 ·Respiratory Medicine and Research ·(unknown), Jean Trédaniel, L. Moreau, (unknown), J. Le Treut, (unknown), S. Hominal, (unknown), (unknown), Olivier Molinier, D. Debieuvre	9
5	Erlotinib en 2e ou 3e ligne pour les cancers bronchiques non à petites cellules sans mutation de l’EGFR : données en vie réelle 2019 ·Revue des Maladies Respiratoires ·D. Debieuvre, L. Moreau, Mathieu Coudert, (unknown), Bernard Asselain, D. Coëtmeur, C. Dayen, François Goupil, Martin Fortin, P Brun, (unknown), (unknown), (unknown), (unknown), M Grivaux	1
6	Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial 2018 ·Annals of Oncology ·Élisabeth Quoix, Clarisse Audigier-Valette, A. Lavolé, Olivier Molinier, Virginie Westeel, Fabrice Barlési, J. Le Treut, Éric Pichon, Jérôme Dauba, Josiane Otto, Patrick Dumont, L. Moreau, J. Madelaine, J. Margery, D. Debieuvre, (unknown), Alexandra Langlais, Franck Morin, Denis Moro‐Sibilot, P.-J. Souquet	0
7	OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study) 2017 ·Journal of Thoracic Oncology ·Nicolas Guibert, Fabrice Barlési, R. Descourt, H. Léna, Benjamin Besse, Michèle Beau‐Faller, Jean Mosser, Éric Pichon, Jean‐Philippe Merlio, L’Houcine Ouafik, F. Guichard, Bénédicte Mastroïanni, L. Moreau, (unknown), Jean‐Christophe Sabourin, Antoinette Lemoine, Pascale Missy, Alexandra Langlais, Denis Moro‐Sibilot, Julien Mazières	1
8	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France 2017 ·Journal of Thoracic Oncology ·Nicolas Guibert, Fabrice Barlési, R. Descourt, H. Léna, Benjamin Besse, Michèle Beau‐Faller, Jean Mosser, Éric Pichon, Jean‐Philippe Merlio, L’Houcine Ouafik, F. Guichard, Bénédicte Mastroïanni, L. Moreau, (unknown), Jean‐Christophe Sabourin, Antoinette Lemoine, Pascale Missy, Alexandra Langlais, Denis Moro‐Sibilot, Julien Mazières	44
9	Association between lung cancer somatic mutations and occupational exposure in never-smokers 2017 ·European Respiratory Journal ·Christophe Paris, Pascal Dô, Bénédicte Mastroïanni, A. Dixmier, Patrick Dumont, Éric Pichon, C. Chouaïd, Bruno Coudert, Pascal Foucher, (unknown), M. Locatelli-Sanchez, Nathalie Baize, Éric Dansin, L. Moreau, Michel Vincent, Pascale Missy, Franck Morin, Denis Moro‐Sibilot, S. Couraud	12
10	No impact of passive smoke on the somatic profile of lung cancers in never-smokers 2015 ·European Respiratory Journal ·S. Couraud, D. Debieuvre, L. Moreau, Patrick Dumont, J. Margery, Élisabeth Quoix, Bernard Duvert, L. Cellerin, Nathalie Baize, (unknown), (unknown), Jacques Cadranel, Pascale Missy, Franck Morin, Jean‐François Mornex, Gérard Zalcman, Pierre-Jean Souquet	19
11	Erlotinibversuscarboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504 2015 ·European Respiratory Journal ·Jacques Cadranel, Radj Gervais, P. Merle, Denis Moro‐Sibilot, Virginie Westeel, L. Bigay-Gamé, Élisabeth Quoix, S. Friard, Fabrice Barlési, Claire Lethrosne, L. Moreau, I. Monnet, Mathieu Salaün, G. Oliviéro, Pierre-Jean Souquet, Martine Antoine, Alexandra Langlais, Franck Morin, Marie Wislez, Gérard Zalcman	6
12	Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy 2010 ·Annals of Oncology ·Séverine Guiu, (unknown), Laure Favier, Isabelle Van Praagh, R. Largillier, B. Weber, David Coeffic, L. Moreau, Frank Priou, Mario Campone, Joseph Gligorov, Laurence Vanlemmens, V. Trillet-Lenoir, Laurent Arnould, Bruno Coudert	17
13	Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial 2005 ·Annals of Oncology ·Bruno Coudert, Laurent Arnould, L. Moreau, P. Chollet, B. Weber, Laurence Vanlemmens, (unknown), N. Tubiana-Mathieu, S. Causeret, J.L. Misset, (unknown), D. Méry-Mignard, J. L. Garnier, P. Fumoleau	77
14	Women and small cell lung cancer: social characteristics, medical history, management and survival 2003 ·Lung Cancer ·B. Mennecier, Marie-Paule Lebitasy, L. Moreau, Guy Hédelin, Ashok Purohit, (unknown), Élisabeth Quoix	18
15	Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study 2001 ·Annals of Oncology ·Élisabeth Quoix, Jean-Luc Breton, Casey L. Daniel, P. Jacoulet, D. Debieuvre, N. Paillot, Romain Kessler, L. Moreau, D. Coëtmeur, É. Lemarié, B. Milleron	38
16	Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy 2000 ·Lung Cancer ·Élisabeth Quoix, Ashok Purohit, (unknown), L. Moreau, (unknown), G. Pauli	51
17	Tolerability of a combination of carboplatin and etoposide phosphate in elderly patients with small cell lung cancer. A multicentric phase II clinical trial 2000 ·Lung Cancer ·Élisabeth Quoix, Jean-Luc Breton, Casey L. Daniel, P. Jacoulet, D. Debieuvre, N. Paillot, Romain Kessler, L. Moreau, D. Coëtmeur, (unknown), (unknown)	3
18	Repeated Inhalation of Low Doses of Cat Allergen That Do Not Induce Clinical Symptoms Increases Bronchial Hyperresponsiveness and Eosinophil Cationic Protein Levels 1999 ·International Archives of Allergy and Immunology ·F. de Blay, (unknown), (unknown), L. Moreau, Catherine Duvernelle, Olivier Kassel, M.C. Kopferschmitt, Bernard Gasser, Christine Demangeat, Gabrielle Pauli, Nelly Frossard	34
19	Weekly systemic combination of cisplatin and interferon α2a in diffuse malignant pleural mesothelioma 1998 ·Lung Cancer ·Ashok Purohit, L. Moreau, (unknown), R. Seibert, G. Pauli, J M Wihlm, Élisabeth Quoix	16
20	Radiochimiothérapie optimisée pour le cancer bronchique non à petites cellules localement évolué 1998 ·Cancer/Radiothérapie ·Élisabeth Quoix, L. Moreau, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact